Congrats on the rebrand! Amazing team. Wishing Formation Bio continued success!!!
Today is an exciting day for me and my co-founder Linhao Zhang, as we announce that TrialSpark has rebranded to Formation Bio. From the very beginning, we have envisioned building the pharma company of the future, one that marries the worlds of technology and pharma and built around velocity and first-principles thinking to ultimately transform how we bring new treatments to patients. We are progressing toward that goal, and have been operating as a clinical stage pharmaceutical company for some time with our own pipeline of drugs. Now, our brand reflects that identity. I am so proud of our teams, whose creativity, collaboration, and focus steer every innovation and milestone here at Formation Bio. While we know that fundamentally transforming how we bring new treatments to patients faster is no easy task and that we have a lot of work ahead of us, we know the impact this will make for our world will be profound. We are so grateful to all our partners, team members, mentors, advisors, and investors for their continued support and look forward to sharing the journey ahead to create this generation's tech-driven pharma company. Sequoia Capital, Michael Moritz, Thrive Capital, Spark Capital, S32, Rehan Verjee, Alex Gorsky, Paul Hudson, Casdin Capital, LLC Yosemite, Lachy Groom, Sanofi, Merck Group, Novartis, Johnson & Johnson, Joe Jimenez, Aditum Bio, Felicis, Mantis Venture Capital, Don DeGolyer, Emerson Collective, Wesley Chan, FPV Ventures, Pegah Ebrahimi, William R., Joshua Kushner, John Doerr, Kareem Zaki, Sound Ventures, Lee Cooper, Julie Grant, Doug Schantz, Dr. Matthias Müllenbeck, MBA, Ling Wong, ArrowMark Partners, Stefano Quintini, Mark Fishman, Jay Parikh, Michael Esquivel, and Sam Altman
Fantastic news!
Congrats!
Naming Expert I Founding Partner of PS212 Naming & Branding
9mowishing everyone at Formation Bio continued success!